Replication-selective oncolytic viruses are being developed for human cancer therapy. We previously developed an attenuated adenovirus Telomelysin), in which the human telomerase reverse transcriptase promoter element drives expression of E1A and E1B genes linked with an internal ribosome entry site. OBP-301 can replicate in, and causes selective lysis of, human cancer cells. Valproic acid (VPA), which is an effective antiepileptic drug, is known to inhibit the histone deacetylase activities. We determined whether the antitumor effect of OBP-301 could be enhanced by VPA in human lung cancer cells. In an in vitro cell viability assay, OBP-301 infection killed four human lung cancer cell lines, H1299, H1299-R5 (a subline of H1299 with a low level of the coxsackievirus and adenovirus receptor (CAR) expression), H460, and A549, more efficiently in the presence of VPA than in its absence. VPA treatment increased CAR expression in all the four lung cancer cells. Consistent with their CAR upregulation, the infection efficiency of adenoviruses in the presence of VPA was significantly higher than that in its absence. The molecular mechanism of this combined effect could be explained by an increase in adenovirus infectivity via VPA-mediated upregulation of CAR. These results suggest that treatment with OBP-301 in combination with VPA is a promising strategy for human lung cancer.
INTRODUCTION
Exploitation of new platforms for treatment of a variety of human malignant cancers is an urgent issue worldwide. Replicationselective oncolytic viruses are being aggressively developed and studied in vitro and in vivo as a promising new therapeutic approach for cancer treatment.
1-3 A variety of mutant or genetically modified adenoviruses has been engineered and these viruses have shown antitumor potency and safety in clinical trials. [4] [5] [6] [7] We previously constructed an adenovirus vector (OBP-301, Telomelysin), in which the human telomerase reverse transcriptase promoter element drives expression of E1A and E1B genes linked with an internal ribosome entry site. We showed that OBP-301 causes efficient selective killing of human cancer cells, but not of normal cells. 8 Although OBP-301 demonstrated a broad-spectrum antitumor efficacy, infectivity of the currently available adenoviral agent, which is derived from human adenovirus serotype 5, varies widely depending on the expression level of coxsackievirus and adenovirus receptor (CAR) on the surface of target cells. 9, 10 Therefore, the improvement and augmentation of adenoviral infectivity is an important challenge to ensure maximal antitumor activity.
Histone deacetylase (HDAC) inhibitors have been proposed as a new type of antitumor agent that have a potential role in the epigenetic modulation of gene expression, induction of cell death, apoptosis and cell cycle arrest in tumor cells. Several HDAC inhibitors are currently being investigated in clinical trials in the cancer therapy as single agents or in combination with different agents. [11] [12] [13] We previously showed that FR901228 (depsipeptide, FK228), a novel type of HDAC inhibitor isolated from the fermentation broth of Chromobacterium violaceum, preferentially increased adenovirus infectivity via upregulation of CAR expression on target tumor cells, leading to a profound oncolytic effect of OBP-301; 14 however, clinical use of FR901228 is limited to the treatment of cutaneous T-cell lymphoma.
Valproic acid (VPA) is a synthetic derivative of propylpentanoic acid that is clinically and widely used as an anticonvulsant and mood-stabilizing drug, mainly in the treatment of epilepsy and bipolar disorder. VPA is also known to inhibit HDAC activities and is undergoing several clinical trials as an antitumor drug in various cancers. 15, 16 Recent studies have demonstrated that VPA improves the antitumor efficacy of oncolytic herpes simplex virus in human glioma cells 17 and of adenovirus-mediated gene therapy in human head and neck squamous cell carcinoma. 18 Although OBP-301 is currently being evaluated as a monotherapy in clinical trials, 19 multimodal therapeutics aimed at enhancing antitumor efficacy might be essential for a successful clinical outcome.
In this study, we examined whether pretreatment with VPA can upregulate CAR levels on the target tumor cells, thereby enhancing the antitumor effect of OBP-301 against human lung cancer cells.
MATERIALS AND METHODS

Cell culture and reagents
The human lung cancer cell lines H1299 (a human non-small-cell lung cancer cell line), H1299-R5 and H460 (a human large-cell lung cancer cell line) were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum, 100 units ml À 1 penicillin, and 100 mg ml À 1 streptomycin at 37 1C in a humidified atmosphere of 5% CO 2 in air. H1299-R5 is a subline of H1299 that is refractory to adenovirus infection due to a low level of CAR expression.
20 A549 (a human lung adenocarcinoma cell line) was cultured 1 in DMEM-F12 medium supplemented with 10% fetal bovine serum, 100 units ml À 1 penicillin, and 100 mg ml À 1 streptomycin at 37 1C in a humidified atmosphere of 5% CO 2 in air. H1299 and A549 cell lines were obtained from the American Type Culture Collection (Manassas, VA). The sodium salt of VPA was purchased from Sigma-Aldrich (St Louis, MO) and was prepared as a 1 M stock solution.
Recombinant adenoviruses OBP-301 (Telomelysin) is a telomerase-specific replication-component adenovirus variant, in which the human telomerase reverse transcriptase promoter element drives the expression of E1A and E1B genes linked with an internal ribosome entry site. 8 A replication-deficient adenoviral vector containing the green fluorescent protein (GFP) gene inserted under the cytomegalovirus promoter (Ad-GFP) was also used.
Cell viability assay
The XTT (sodium 3 0 -[1-(phenylaminocarbonyl)-3, 4-tetrazolium]-bis(4-methoxy-6-nitro)benzene sulfonic acid hydrate) assay was performed to measure the cell viability. Briefly, the cells were seeded at a density of 1 Â 10 3 cells per well in 96-well plates 16-20 h before viral infection and were infected with OBP-301 at a multiplicity of infection (MOI) of 0, 1, 10 or 50 plaque-forming units per cell. Cell viability was determined at the indicated times by using a Cell Proliferation Kit II (Roche Applied Science, Mannheim, Germany) according to the manufacturer's protocol.
Flow cytometric analysis
The cells (2 Â 10 5 cells) were labeled with a mouse monoclonal anti-CAR antibody (RmcB; Upstate Biotechnology, Lake Placid, NY) for 30 min on ice. An isotype-matched normal mouse IgG1 conjugated to fluorescein isothiocyanate (Serotec, Oxford, UK) was used as a control. The cells were then incubated with a fluorescein isothiocyanate-conjugated rabbit antimouse IgG second antibody (Zymed Laboratories, South San Francisco, CA) and were analyzed using flow cytometry (FACSCalibur, Becton Dickinson, San Jose, CA). Relative mean fluorescence intensity was determined by calculating the quotient of the mean fluorescence intensity in antibodytreated cells and nontreated cells.
Quantitative real-time PCR analysis
The DNA was extracted using the QIAamp DNA Mini Kit (Qiagen, Valencia, CA), and quantitative real-time PCR analysis of E1A gene expression was performed using a LightCycler instrument (Roche Molecular Diagnostics, Indianapolis, IN). The sequences of the specific primers used for E1A amplification were: sense: 5 0 -CCT GTG TCT AGA GAA TGC AA-3 0 and antisense: 5 0 -ACA GCT CAA GTC CAA AGG TT-3 0 . PCR amplification began with a 600 s denaturation step at 95 1C, which was followed by 40 cycles of 
Fluorescent microscopy and fluorescent microplate reader
Human lung cancer cells were infected with Ad-GFP at an MOI of 1 for 24 h. Cells were photographed using an IX71 fluorescent microscopy (Olympus, Tokyo, Japan). The level of expression of GFP fluorescence was measured using fluorescent microplate reader (DS Pharma Biomedical, Osaka, Japan) with excitation/emission at 485 nm/528 nm.
Statistical analysis
Significant differences among the groups were assessed by Student's t-test using values from the original data analysis. P-values o0.05 were considered statistically significant.
RESULTS
Antitumor efficacy of OBP-301 plus VPA against human lung cancer cells We first evaluated the antitumor efficacy of a combination of OBP-301 and VPA in vitro. H1299, H1299-R5 (a subline of H1299 with a low level of CAR expression), H460 and A549 cells were treated with or without 1 mM of VPA, and then infected with the indicated MOI of OBP-301 at 24 h after VPA treatment. Cell viability was assessed using the XTT assay at 2, 3 and 5 days after infection ( Figure 1 ). VPA treatment increased the antitumor efficacy of OBP-301 in all of the cell lines that we tested. In particular, VPA treatment dramatically increased the antitumor efficacy of OBP-301 at 5 days after infection when OBP-301 was used at 0.5 MOI in H1299 and A549 cells, at 1 MOI in A549 cells and at 10 MOI in H460 cells. These results suggested that VPA enhanced the antitumor efficacy of OBP-301 against human lung cancer cells.
Expression of CAR on human lung cancer cells after VPA treatment To explore the mechanism by which VPA enhanced the antitumor efficacy of OBP-301, we next examined whether VPA upregulates CAR expression on the cell surface. H1299, H1299-R5, H460 and A549 cells were treated with or without 1 mM of VPA for 24 h and 72 h. Cancer cells were then subjected to flow cytometric analysis. VPA treatment induced CAR expression in a time-dependent manner in all the four lung cancer cell lines (Figure 2 ). The CAR expression was increased in the VPA-treated cells by 1.3 to 3.1-fold compared with the VPA-nontreated cells (Figure 2b) .
Infectivity of the oncolytic adenovirus in human lung cancer cells after VPA treatment We further examined the effect of VPA on OBP-301 infectivity by measuring E1A DNA copy number. H1299, H1299-R5, H460 and A549 cells were treated with or without 1 mM VPA, and infected with 1 MOI of OBP-301 24 h later. The cells were harvested at 2 h after infection and E1A copy number was analyzed using quantitative real-time PCR analysis. As shown in Figure 3a , the E1A copy number in the four lung cancer cell lines was increased by VPA treatment: the VPA-treated to VPA-nontreated ratio was 1.8, 2.1, 1.2 and 1.2 for H1299, H1299-R5, H460 and A549 cells, respectively. Moreover, to confirm the effect of VPA on OBP-301 infectivity, we investigated the expression of adenovirus-derived protein in cancer cells. Using fluorescent microscopy and fluorescent microplate reader, the expression of GFP was evaluated in the cells treated with or without 1 mM VPA, followed by the replication-defective GFP-expressing adenovirus, Ad-GFP, infection 24 h later (Figure 3b) . The fluorescence intensity of GFP in VPA-treated H1299, H1299-R5, H460 and A549 cells was significantly higher than that in control cells (Figure 3c ). These findings were consistent with the results of E1A copy number as analyzed using quantitative real-time PCR. These results suggest that the infectivity of OBP-301 for H1299, H1299-R5, H460 and A549 cells was increased by VPA treatment.
Replication of OBP-301 in human lung cancer cells after VPA treatment To determine the effect of VPA on OBP-301 replication, we measured the E1A copy number in the presence and absence of VPA treatment. H1299, H1299-R5, H460 and A549 cells were infected with OBP-301 24 h after VPA treatment, were harvested at various time points over 72 h after infection of OBP-301 and EIA copy number was then analyzed using quantitative real-time PCR analysis. The ratios were normalized by dividing the value of 
DISCUSSION
Virotherapy by oncolytic viruses including adenoviral agent OBP-301 is quite a promising therapeutic approach for cancer and OBP-301 has been shown to efficiently kill a variety of human cancer cells. 8 Virus infectivity is an essential aspect in achieving the who reported that VPA increases the mRNA level of CAR in NT8e head and neck squamous cell carcinoma. We previously showed that FR901228, a novel type of HDAC inhibitor, increases the CAR expression level on the surface of H460 and A549 cells, but not of H1299 cells. 14 In the present study, VPA increased the CAR expression level on the surface of H1299, H460 and A549 cells, and H1299 cells was more sensitive to VPA than H460 and A549 cells (Figure 2 ). The reason why the CAR expression in these lung cancer cell lines treated with VPA is different from the result treated with FR901228 is unclear. However, it is possible that the difference in sensitivity to FR901228 and VPA between these cell lines is due to differences in specificity for HDACs; for example, FR901228 specifically inhibits HDAC1 and 2, and VPA inhibits class I and IIa HDACs. 12 One of the advantages of replication-competent oncolytic adenoviruses is that less virus particles are required for treatment, because viruses can be produced in tumor tissues by replication. We used the replication-defective Ad-GFP at a MOI of 1 to directly evaluate the effect of VPA on increased virus infectivity of the oncolytic virus, and we confirmed increased infection efficiency of the adenovirus following VPA treatment (Figures 3b and c) . These results are also consistent with the results reported by Kothari et al. 18 Regarding the effect of VPA on viral replication, Hö ti et al.
21
reported that VPA inhibited adenoviral replication by induction of p21, which is cell-cycle-regulating protein. However, in our study, VPA treatment did not affect the replication of OBP-301 ( Figure 4 ) though VPA upregulated p21 expression in H1299 and H1299-R5 cells (Supplementary Figure S1a) . Additionally, the VPA-mediated p21 expression was markedly reduced in OBP-301-infected cells (Supplementary Figure S1b) . These data are consistent with our recent report that adenoviral E1A suppresses the expression of p21, 22 suggesting that E1A would inhibit antagonistic effect of VPA on antitumor effect of oncolytic virus through reduction of p21 expression.
It has been reported that VPA itself has several antitumor effects including alteration of transcriptional activity, 15, 16 stimulation of antitumor immune systems 23 and inhibition of tumor angiogenesis. 24 We previously showed that OBP-301 replication produced the endogenous danger signaling molecule, uric acid, in infected human cancer cells. This uric acid stimulated dendritic cells to produce interferon-g (IFN-g) and interleukin 12. Subsequently, IFN-g release upregulated expression of the endogenous proteasome activator PA28 in cancer cells and resulted in the induction of cytotoxic T-lymphocytes. 25 Moreover, OBP-301 induces an antiangiogenic effect by stimulating host immune cells to produce antiangiogenic mediators such as IFN-g. 26 These findings suggest that combining OBP-301 with VPA should exert a stronger antitumor effect than either agent alone. Furthermore, VPA has been shown to enhance radiosensitization in human cancer cells. 27 We previously reported that OBP-301 enhances radiosensitization in human cancer cells by inhibition of the DNA repair machinery. 28 Based on these findings, combination therapy with OBP-301, VPA and radiation is an exceedingly promising antitumor therapy.
In summary, we showed that VPA increases cellular CAR expression, which, in turn, facilitates virus infection, thereby enhancing antitumor effects in cancer cells. Our data support the possibility that combination of the telomerase-specific adenovirus agent OBP-301 with VPA is a promising strategy for cancer treatment.
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